New data demonstrating the strength of Novartis' hematology portfolio to be presen...
Novartis announced today that new data, including a late-breaking presentation on Tasigna® (nilotinib) 200 mg capsules in a form of chronic myeloid leukemia, demonstrate the strength of the...
News-Medical-Net,
Wed Dec 02 04:00:25 PST 2009
• Found on Yahoo! News